ICER rates Astellas' potential menopausal symptom drug as promising at about $2K per year
The Institute for Clinical and Economic Review (ICER) on Thursday published a new evidence report for Astellas Pharma’s fezolinetant, recommending that …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.